Company Invion Limited

Equities

IVX

AU000000IVX4

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 10:20:32 2024-04-23 pm EDT			5-day change	1st Jan Change
0.006 ^AUD	0.00%		+20.00%	+20.00%

Mar. 05	Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results	MT
Feb. 27	Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Invion Limited is an Australia-based life sciences company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is engaged in the clinical development of a PhotoDynamic Therapy (PDT) for cancer. Its photosensitizer (the agent used in PDT) is called IVX-PDT and is based on Photosoft Technology. Its PDT is an alternative to surgery, and in contrast to radiotherapy and chemotherapy, which are immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumor by leukocytes. It produces topical and intravenous products suitable for use in skin cancer and in solid tumors, such as those present in ovarian, prostate and lung cancer. It is developing a topical formulation of its photosensitizing agent, IVX-PDT, to treat superficial Basal Cell Carcinoma (sBCC), Actinic Keratosis (AK) and Squamous Cell Cancer (SCC).

Number of employees: 4

AUD in Million	2022	Weight	2023	Weight	Delta
Clinical-stage Life Sciences 100.0 %	3	100.0 %	4	100.0 %	+24.70%

AUD in Million	2022	Weight	2023	Weight	Delta
Australia 100.0 %	3	100.0 %	4	100.0 %	+24.70%

Managers	Title	Age	Since
Thian Chew CEO	Chief Executive Officer	-	17-11-30
Melanie Leydin DFI	Director of Finance/CFO	51	20-07-12
Brendon Lau IRC	Investor Relations Contact	-	-
Claire Newstead-Sinclair SEC	Corporate Secretary	-	21-10-31

Members of the board	Title	Age	Since
Alistair Bennallack BRD	Director/Board Member	-	20-10-21
Thian Chew CEO	Chief Executive Officer	-	17-11-30
Alan Yamashita BRD	Director/Board Member	74	19-02-11
Rob Merriel BRD	Director/Board Member	-	20-08-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,421,632,206	3,271,816,919 ( 50.95 %)	0	50.95 %

Name	Equities	%	Valuation
Thian Chew 8.512 %	546,857,721	8.512 %	2 M $
Shengli Wang 6.365 %	408,940,371	6.365 %	2 M $
Rmwc Pty Ltd. 4.896 %	314,547,156	4.896 %	1 M $
Honsue Cho 4.430 %	284,626,482	4.430 %	1 M $
Jun Lin Mei 4.242 %	272,500,000	4.242 %	1 M $
Acslnc Pty Ltd. 3.579 %	229,950,000	3.579 %	899 105 $
Yong Chen 3.164 %	203,253,079	3.164 %	794 720 $
Dandan Wang 1.630 %	104,719,526	1.630 %	409 453 $
Surfit Capital Pty Ltd. 1.557 %	100,000,000	1.557 %	391 000 $
Sheng Wei Ou 1.203 %	77,304,171	1.203 %	302 259 $

Invion Ltd.

692 High Street

3102, East Kew

+61 3 9692 7222

http://www.inviongroup.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
INVION LIMITED	+20.00%	25.07M
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+48.26%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research